All In Biotech

Drug Trial Radar · NCT00434096

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

A Randomized Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen (SR141716 20 mg), Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Patients With Dyslipidemia.

Last checked: Nov 20, 2026Latest source record: Jul 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 915 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

915

Actual

Start

Feb 2007

Primary completion

Nov 2008

Study completion Feb 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: * To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area. * To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks. * To evaluate the pharmacokinetics of SR141716.

Conditions

  • Obesity

Interventions

  • rimonabant (SR141716)Drug

    oral administration once daily

  • placeboDrug

    oral administration once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. body weight: relative change from baselineTime frame: Week 52
  2. triglycerides: relative change from baselineTime frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.